Showing results (31-40 of 59) with videos related to
Sort By:
Pageof 6
Science Advances|September 28, 2022
Accurate detection of benign and malignant renal tumor subtypes with MethylBoostER: An epigenetic marker-driven learning frameworkSabrina H Rossi, Izzy Newsham, Sara Pita, et al.Nature Genetics|June 24, 2003
OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancerGrant C Sellar, Karen P Watt, Genevieve J Rabiasz, et al.Endocrine-Related Cancer|January 7, 2015
HES5 silencing is an early and recurrent change in prostate tumourigenesisCharles E Massie, Inmaculada Spiteri, Helen Ross-Adams, et al.The Journal of Pathology|April 16, 2015
A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapyNelma Pertega-Gomes, Sergio Felisbino, Charlie E Massie, et al.Cancer Cell|December 11, 2007
The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxelAhmed Ashour Ahmed, Anthony D Mills, Ashraf E K Ibrahim, et al.Scientific Reports|July 19, 2017
Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder CancerK M Patel, K E van der Vos, C G Smith, et al.Nature Genetics|December 10, 2013
Inactivating CUX1 mutations promote tumorigenesisChi C Wong, Inigo Martincorena, Alistair G Rust, et al.The New England Journal of Medicine|February 12, 2015
Effect of mutation order on myeloproliferative neoplasmsChristina A Ortmann, David G Kent, Jyoti Nangalia, et al.European Urology|November 18, 2015
The Early Effects of Rapid Androgen Deprivation on Human Prostate CancerGreg L Shaw, Hayley Whitaker, Marie Corcoran, et al.EMBO Molecular Medicine|April 17, 2014
HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle networkAntonio Ramos-Montoya, Alastair D Lamb, Roslin Russell, et al.Pageof 6